Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prokidney (PROK) Research & Development (2022 - 2025)

Prokidney (PROK) has disclosed Research & Development for 4 consecutive years, with $26.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 14.17% to $26.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $119.7 million, a 8.45% increase, with the full-year FY2024 number at $127.7 million, up 19.64% from a year prior.
  • Research & Development was $26.8 million for Q3 2025 at Prokidney, up from $25.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $39.8 million in Q4 2024 to a low of $11.6 million in Q2 2022.
  • A 4-year average of $26.4 million and a median of $26.8 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 128.1% in 2023, then fell 14.17% in 2025.
  • Prokidney's Research & Development stood at $20.9 million in 2022, then grew by 7.84% to $22.5 million in 2023, then soared by 76.58% to $39.8 million in 2024, then tumbled by 32.58% to $26.8 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's Research & Development are $26.8 million (Q3 2025), $25.9 million (Q2 2025), and $27.3 million (Q1 2025).